ELEMENT | CURRENT QUARTER | SIMILAR QUARTER FOR PREVIOUS YEAR | % CHANGE CURRENT | PREVIOUS QUARTER | % CHANGE PREVIOUS |
NET PROFIT (LOSS) | 237.6 | 97.7 | 143.19 | 99.4 | 139.03 |
GROSS PROFIT (LOSS) | 210.9 | 193.5 | 8.99 | 225.9 | -6.64 |
OPERATIONAL PROFIT (LOSS) | 48 | 42.6 | 12.68 | 91.3 | -47.43 |
ELEMENT | CURRENT PERIOD | SIMILAR PERIOD FOR PREVIOUS YEAR | % CHANGE |
NET PROFIT (LOSS) | 337 | 188.9 | 78.4 |
GROSS PROFIT (LOSS) | 436.8 | 399.9 | 9.23 |
OPERATIONAL PROFIT (LOSS) | 139.4 | 121 | 15.21 |
EARNING OR LOSS PER SHARE, RIYALS | 2.81 | 1.98 | - |
All figures are in (Millions) Saudi Arabia, Riyals |
ELEMENT | EXPLAINATION |
REASONS OF INCREASE (DECREASE) FOR QUARTER COMPARED WITH SAME QUARTER LAST YEAR | Sales rise by 16% In addition to the net capital gains due to sell its entire stake in Eirgen Pharma for Opko at total value of SR 151.3 million, which after deducting the costs and expenses of the legal and financial agreements. |
REASONS OF INCREASE (DECREASE) FOR PERIOD COMPARED WITH SAME PERIOD LAST YEAR | Sales rise by 16% In addition to the net capital gains due to sell its entire stake in Eirgen Pharma for Opko at total value of SR 151.3 million, which after deducting the costs and expenses of the legal and financial agreements. |
REASONS OF INCREASE (DECREASE) FOR QUARTER COMPARED WITH PREVIOUS QUARTER | Net capital gains due to sell its entire stake in Eirgen Pharma for Opko at total value of SR 151.3 million, which after deducting the costs and expenses of the legal and financial agreements. |
RECLASSIFICATIONS IN QUARTERLY FINANCIAL RESULTS | It has been classified and displayed the numbers of 2014 to compare it with 2015. |
OTHER NOTES |
Earnings per share has been calculated using the weighted average method, costing 78,437,500 shares to reflect the increase in the share capital from 120,000,000 shares to 120 million shares, which has been approved at EGM on 17/04/2014. Knowing that the weighted average number of shares during the six months ended June 30, 2014 amounted to 95524306 shares. |
distributed by |